Pregabalin Capsule
Product Images NDC 71205-639

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-639-30 (Pregabalin 100mg 90s)

Packaging label for Pregabalin 100 mg capsules, 30 count, labeled for oral administration. The label shows the ProficientRx brand and mentions the capsules are hard gelatin with 100 mg pregabalin each. Manufacturer is Alkem Laboratories Ltd., Mumbai, India. The label includes NDC 71205-639-30 and indicates the product is Schedule C-V (controlled substance).*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A mathematical formula for calculating creatinine clearance (CLCr) is shown, including variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. This formula is part of the drug facts or clinical information related to Pregabalin.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar chart showing responder rates in two clinical studies labeled Study E1 and Study E3. The vertical axis represents responder rate percentages from 0% to 60%. Study E1 compares placebo and various dosages of pregabalin from 50 mg/day to 600 mg/day given twice daily (BID). Study E3 compares placebo, 600 mg/day pregabalin BID, and 600 mg/day pregabalin three times daily (TID). Each bar is labeled with responder percentages and sample sizes (N). A note indicates asterisked bars are statistically significant versus placebo.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line chart illustrating seizure reduction as median percent change from baseline plotted against daily dose in mg/day. The chart compares seizure reduction across three studies (E1 BID, E2 TID, and E3 BID/TID) with different dosing regimens, showing increased seizure reduction with higher doses up to 600 mg/day, and includes p-values indicating statistical significance for dose effects versus placebo.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the percent of patients improved against the percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and a placebo group, showing trends of patient improvement across different pain improvement percentages.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line chart showing percent improvement from baseline to Week 12 BOCF on the x-axis and percent of subjects improved on the y-axis. Two lines represent the improvement trends for Pregabalin and Placebo groups.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved from baseline to Week 16 biopsy for Pregabalin versus placebo. The x-axis shows percent improvement from baseline to Week 16, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin (solid) and placebo (dashed), indicating higher improvement rates with Pregabalin over placebo across the measured range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares the effects of Pregabalin 100 mg taken three times a day with placebo, illustrating higher improvement rates for Pregabalin across various thresholds.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing percent improvement in pain from baseline plotted against time in hours. Four curves represent Pregabalin dosed at 75 mg, 150 mg, and 300 mg twice a day, and a placebo control, illustrating pain relief effectiveness over approximately 10 hours.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph comparing the percent improvement in pain from baseline with the percent of patients improved. It shows three lines for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating treatment response distribution across different levels of pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph comparing the percent improvement in pain from baseline with three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows the percent of patients improved on the vertical axis and percent improvement in pain on the horizontal axis, with both Pregabalin doses indicating higher patient improvement compared to placebo.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 600 mg daily doses compared to placebo. The graph illustrates the relationship between dosage and pain improvement among patients over a range of percent improvements.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus Placebo. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents time in days. The Pregabalin group shows a consistently higher percentage of subjects without LTR compared to the Placebo group throughout the timeline.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of Pregabalin, illustrating the molecular arrangement of atoms including a carboxyl group (CO2H) and an amino group (NH2). The image depicts the 2D structural formula of the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.